CIK 0001157601 · Large accelerated filer
MADRIGAL PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- MDGL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (267) 824-2827
- Business address
- 1001 CONSHOHOCKEN STATE ROAD, SUITE 2-350, WEST CONSHOHOCKEN, PA
- Former names
- MADRIGAL PHARMACEUTICALS, INC., SYNTA PHARMACEUTICALS CORP
- Open-market buys, last 90 days
- $35,023,032
- in 1 filing
- Open-market sales, last 90 days
- $7,011,938
- in 3 filings, $6.7M under 10b5-1 plans
Net +$28,011,094. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −4,701 | $343.85 | $1.6M | 5,140 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Sale | −1,412 | $344.76 | $487K | 3,728 |
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award | +2,061 | 5,789 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −6,825 | 4,375 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Option exercise · Stock Option (Right to Buy) | −7,288 | 3,062 | ||
| 2025-03-05 | Waltermire Robert E. Senior VP, Chief Pharma Dev. | Grant or award · Stock Option (Right to Buy) | +1,157 | 1,157 | ||
| 2025-03-05 | Taub Rebecca Pres., R&D, and CMO | Grant or award | +4,382 | 461,044 | ||
| 2025-03-05 | Taub Rebecca Pres., R&D, and CMO | Grant or award · Stock Option (Right to Buy) | +7,381 | 7,381 | ||
| 2025-03-05 | Kelley Shannon T General Counsel | Grant or award | +3,187 | 10,477 | ||
| 2025-03-05 | Kelley Shannon T General Counsel | Grant or award · Stock Option (Right to Buy) | +5,368 | 5,368 | ||
| 2025-03-05 | Huntsman Carole Chief Commercial Officer | Grant or award | +3,386 | 11,990 | ||
| 2025-03-05 | Huntsman Carole Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +5,703 | 5,703 | ||
| 2025-03-03 | Kelley Shannon T General Counsel | Sale 10b5-1 | −415 | $335.00 | $139K | 7,290 |
| 2025-03-03 | Dier Mardi SVP and CFO | Sale 10b5-1 | −1,187 | $325.89 | $387K | 7,688 |
| 2025-03-03 | Dier Mardi SVP and CFO | Sale 10b5-1 | −774 | $323.54 | $250K | 6,914 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −71 | $313.08 | $22K | 10,367 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −200 | $314.74 | $63K | 10,167 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −300 | $320.21 | $96K | 9,867 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −200 | $323.65 | $65K | 9,667 |
| 2025-03-03 | Huntsman Carole Chief Commercial Officer | Sale 10b5-1 | −200 | $324.59 | $65K | 9,467 |
Page 25 of 82 · 1,629 trades